EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Jan. 20, 2015 (GLOBE NEWSWIRE) --

What: 

EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based pharmaceutical company focused on the global development of biosimilar monoclonal antibodies, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Amit Munshi, President and Chief Executive Officer will ring the Closing Bell. 

Where:

Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:

Wednesday, January 21, 2015 – 3:45 p.m. to 4:00 p.m. ET         

EPIRUS Biopharmaceuticals, Inc. Media Contact:
Andrea Flynn
[phone]
[e-mail] 

Nasdaq MarketSite:
Christine Barna
[phone]
[e-mail]

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/

Webcast:

A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS):

EPIRUS is global biosimilar company focused on improving patient access to important medicines.  EPIRUS’ operationally synergistic pipeline of biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab).  The reference products for these product candidates – Remicade^®, Humira^® and Actemra^®, respectively – together generated over $20 billion in global sales in 2013.

The company’s strategy for commercial success and profitability relies on targeted approaches for diverse and competitive global markets.

For large, developed markets, such as US and Europe, EPIRUS plans to commercialize its products using a combination of direct sales, licensing and local distributors.

For high-growth global markets where local manufacturing confers strategic and operational advantages, EPIRUS intends to use its SCALE™ platform to deliver an In Market, For Market™ manufacturing solution with local partners.

For emerging markets with accessible regulatory frameworks for biosimilars, EPIRUS develops partnerships with local companies to accelerate regulatory approval and commercialize its products.

More information about EPIRUS can be found at www.epirusbiopharma.com.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets.  As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.nasdaqomx.com.

-NDAQA-